State Street SPDR S&P Health Care Services ETF

XHS

Market cap $207M

With well over 170 ETFs on the market covering diverse investment strategies, State Street offers a prime window into which funds — and market trends — are leading the pack in the near term. Key Takeaways: Across State Street's 170+ ETFs, the top five performers this past month are all tied to the healthcare industry.

The State Street SPDR S&P Health Care Services ETF (XHS) made its debut on 09/28/2011, and is a smart beta exchange traded fund that provides broad exposure to the Health Care ETFs category of the market.

Designed to provide broad exposure to the Healthcare - Services segment of the equity market, the State Street SPDR S&P Health Care Services ETF (XHS) is a passively managed exchange traded fund launched on September 28, 2011.

Biotech, China, insurance and healthcare ETFs led June gains as strong earnings, AI optimism and easing geopolitical fears lifted markets.

XHS hits a new 52-week high as healthcare-services stocks gain from steady earnings and defensive investor positioning.

Investors are questioning the staying power of medical technology (medtech) stocks, which have fallen from grace since the COVID-19 pandemic. The starting point is to distinguish between medtech and other healthcare industries.

After a 50%+ run from lows last April through highs in mid-January, the Biotech group has been trending sideways over the last few months. Biotech hasn't garnered much attention lately, with all the coverage of the Iran War and the AI Doom trade that's been taking down software stocks even as AI infrastructure stocks continue to surge.

Healthcare and biotech led last week's winners, with EPHE, BBC, HELX, XHS and SURI topping ETF gains as markets slid on AI worries and Fed uncertainty.

The healthcare sector has experienced one of its most significant de-ratings in 35 years, with valuations now at a 30% discount to the broader market. Healthcare trades at historical valuation discounts across multiple metrics.

Outlook for pharma sector as Trump pushes for regulatory changes. The impact of tariffs on drugmakers.